This book presents an overview of antimicrobial peptides (AMPs), their mechanisms of antimicrobial action, other activities, and various problems that must still be overcome regarding their clinical application. Divided into four major parts, the book begins with a general overview of AMPs (Part I), and subsequently discusses the various mechanisms of antimicrobial action and methods for researching them (Part 2). It then addresses a range of activities other than antimicrobial action, such as cell penetration, antisepsis, anticancer, and immunomodulatory activities (Part 3), and explores the prospects of clinical application from various standpoints such as the selective toxicity, design, and discovery of AMPs (Part 4). A huge number of AMPs have been discovered in plants, insects, and vertebrates including humans, and constitute host defense systems against invading pathogenic microorganisms. Consequently, many attempts have been made to utilize AMPs as antibiotics. AMPs could help to solve the urgent problem of drug-resistant bacteria, and are also promising with regard to sepsis and cancer therapy. Gathering a wealth of information, this book will be a bible for all those seeking to develop antibiotics, anti-sepsis, or anticancer agents based on AMPs.

The detrimental effects of incomplete data sets on the results of clinical trials are both well known and all too commonly recurrent. It is essential that the correct statistical methodology be applied in order to effectively analyse the results of trials affected by missing data.

Missing Data in Clinical Trials provides a comprehensive account of the problems arising when data from clinical and related studies are incomplete, and presents the reader with approaches to effectively address them. The text provides a critique of conventional and simple methods before moving on to discuss more advanced approaches. The authors focus on practical and modeling concepts, providing an extensive set of case studies to illustrate the problems described.

Provides a practical guide to the analysis of clinical trials and related studies with missing data. Examines the problems caused by missing data, enabling a complete understanding of how to overcome them. Presents conventional, simple methods to tackle these problems, before addressing more advanced approaches, including sensitivity analysis, and the MAR missingness mechanism. Illustrated throughout with real-life case studies and worked examples from clinical trials. Details the use and implementation of the necessary statistical software, primarily SAS.

Missing Data in Clinical Trials has been developed through a series of courses and lectures. Its practical approach will appeal to applied statisticians and biomedical researchers, in particular those in the biopharmaceutical industry, medical and public health organisations. Graduate students of biostatistics will also find much of benefit.

Fullerens, Graphenes and Nanotubes: A Pharmaceutical Approach shows how carbon nanomaterials are used in the pharmaceutical industry. While there are various books on the carbonaceous nanomaterials available on the market, none approach the subject from a pharmaceutical point-of-view. In this context, the book covers different applications of carbonaceous nanomaterials. Chapters examine different types of carbon nanomaterials and explore how they are used in such areas as cancer treatments, pulse sensing and prosthetics. Readers will find this book to be a valuable reference resource for those working in the areas of carbon materials, nanomaterials and pharmaceutical science.

Pharmacogenetics, Volume 83, the newest volume in the Advances in Pharmacology series, presents a variety of chapters and the best authors in the field, with this release highlighting regulatory perspectives, the implementation of pharmacogenetics in everyday clinical setting, imaging in pharmacogenetics, pharmacoepidemiology in pharmacogenetics, epigenetics and micro RNA in pharmacogenetics, ethnicity in pharmacogenetics, pediatric pharmacogenetics, pharmacogenetics and adverse drug reactions, and cytochrome P450 pharmacogenetics amongst other important topics. This series presents an essential resource for pharmacologists, immunologists, and biochemists alike.

This book presents an extensive study on the effectiveness of recent regulations on pharmaceutical prices in India, exploring the weaknesses in the design and implementation of pharmaceutical price controls and investigating what can be done to fix the broken system. In addition, it examines the extent to which essential medicines are actually made affordable by price controls. The book argues that companies make the pharmaceutical price control regime largely ineffective by coordinating to increase pre-regulation prices; by diversifying horizontally away from the regulated markets and increasing prices in the unregulated markets; by manipulating trade margins; and by refusing to comply with the regulation because the penalties remains negligible. The book draws on extensive empirical research involving India's 2013 Drug Price Control Order and widely-used medicines such as paracetamol and metformin to illustrate how firms have weakened regulation. It argues that the regulatory regime can be strengthened by using systematic analysis of product- and region-level data in the Indian pharmaceutical industry, and by screening for the strategies that firms currently employ to circumvent regulation. In closing, it discusses recent efforts to strengthen the implementation of price controls in India and expanding the scope of price controls to medical devices.

Substance Use Disorders: Assessment and Treatment is a summary of everything a therapist should know about substance abuse in one easy-to-read comprehensive book. The book begins with a discussion of the pharmacology of specific drug classes (opioids, hallucinogens, etc.) and the epidemiology of abuse. It then presents psychological theories of substance abuse, the initiation and progression of substance abuse disorders, issues of prevention and early intervention, and screening and assessment for substance abuse (including specific tests for assessment) and discusses in detail the various treatment methodologies available. Two final chapters explore issues relevant to special populations and legal and ethical considerations, regarding issues such as confidentiality and coerced treatment.
Key Features
* A synthesis of the current research and clinical literature
* Includes strengths and weaknesses of commonly used psychometric assessment measures
* Presentation and review of a complete Psychosocial/Substance Use Assessment form
* Discussion of treatment settings and criteria for placement decisions
* Discussion of treatment alternatives and effectiveness of major pharmacological and psychotherapeutic approaches
* Discussion of factors leading to Relapse, and components of Relapse Prevention programs

Medicinal Chemistry: Fundaments presents the cycle of the life of drugs, their physico-chemical properties, and consequences that arise in development. The fundamental concepts of Medicinal Chemistry (pharmacophore, prodrugs, Lipinsky rules) are also presented, including discussions on specific concerns of the European Pharmacopeia - the industrialist's bible - its role, and a description of the monographs of active principles.

Clinical research is heavily regulated and involves coordination of numerous pharmaceutical-related disciplines. Each individual trial involves contractual, regulatory, and ethics approval at each site and in each country. Clinical trials have become so complex and government requirements so stringent that researchers often approach trials too cautiously, convinced that the process is bound to be insurmountably complicated and riddled with roadblocks. A step back is needed, an objective examination of the drug development process as a whole, and recommendations made for streamlining the process at all stages. With Intelligent Drug Development, Michael Tansey systematically addresses the key elements that affect the quality, timeliness, and cost-effectiveness of the drug-development process, and identifies steps that can be adjusted and made more efficient. Tansey uses his own experiences conducting clinical trials to create a guide that provides flexible, adaptable ways of implementing the necessary processes of development. Moreover, the processes described in the book are not dependent either on a particular company structure or on any specific technology; thus, Tansey's approach can be implemented at any company, regardless of size. The book includes specific examples that illustrate some of the ways in which the principles can be applied, as well as suggestions for providing a better context in which the changes can be implemented. The protocols for drug development and clinical research have grown increasingly complex in recent years, making Intelligent Drug Development a needed examination of the pharmaceutical process.

Progress in Drug Research is a prestigious book series which provides extensive expert-written reviews on a wide spectrum of highly topical areas in current pharmaceutical and pharmacological research. Founded in 1959 by its current editor, the series has moved from its initial focus on medicinal chemistry to a much wider scope. Today it encompasses all fields concerned with the development of new therapeutic drugs and the elucidation of their mechanisms of action, reflecting the increasingly complex nature of modern drug research. Invited authors present their biological, chemical, biochemical, physiological, immunological, pharmaceutical, toxicological, pharmacological and clinical expertise in carefully written reviews and provide the newcomer and the specialist alike with an up-to-date comprehensive list of prime references. Each volume of Progress in Drug Research contains fully cross-referencing indices which link the books together, forming a virtually encyclopaedic work. The series thus serves as an important, time-saving source of information for researchers concerned with drug research and all those who need to keep abreast of the many recent developments in the quest for new and better medicines.

Handbook of Pharmaceutical Wet Granulation: Theory and Practice in a Quality by Design Paradigm offers a single and comprehensive reference dedicated to all aspects of pharmaceutical wet granulation, taking a holistic approach by combining introductory principles with practical solutions. Chapters are written by international experts across industry, academic and regulatory settings, and cover a wide spectrum of relevant and contemporary wet granulation topics, techniques and processes. The books' focus on process analytical technology, quality by design principles, granulation equipment, modeling, scale-up, control and real time release makes it a timely and valuable resource for all those involved in pharmaceutical wet granulation.

Psychiatry today is a barren tundra, writes medical historian Edward Shorter, where drugs that don't work are used to treat diseases that don't exist. In this provocative volume, Shorter illuminates this dismal landscape, in a revealing account of why psychiatry is "losing ground" in the struggle to treat depression.
Naturally, the book looks at such culprits as the pharmaceutical industry, which is not inclined to market drugs once the patent expires, leading to the endless introduction of new--but not necessarily better--drugs. But the heart of the book focuses on an unexpected villain: the FDA, the very agency charged with ensuring drug safety and effectiveness. Shorter describes how the FDA permits companies to test new products only against placebo. If you can beat sugar pills, you get your drug licensed, whether or not it is actually better than (or even as good as) current medications, thus sweeping from the shelves drugs that may be superior but have lost patent protection. The book also examines the FDA's early power struggles against the drug industry, an influence-grab that had little to do with science, and which left barbiturates, opiates, and amphetamines all underprescribed, despite the fact that under careful supervision they are better at treating depression, with fewer side effects, than the newer drugs in the Prozac family. Shorter also castigates academia, showing how two forms of depression, melancholia and nonmelancholia--"as different from each other as chalk and cheese"--became squeezed into one dubious classification, major depression, which was essentially a political artifact born of academic infighting.
An astonishing and troubling look at modern psychiatry, Losing Ground is a book that is sure to spark controversy for years to come.

Drug Targeting and Stimuli Sensitive Drug Delivery Systems covers recent advances in the area of stimuli sensitive drug delivery systems, providing an up-to-date overview of the physical, chemical, biological and multistimuli-responsive nanosystems. In addition, the book presents an analysis of clinical status for different types of nanoplatforms. Written by an internationally diverse group of researchers, it is an important reference resource for both biomaterials scientists and those working in the pharmaceutical industry who are looking to help create more effective drug delivery systems.

The book deals with the subject of depression and its causes and answers a number of questions that should be of interest to any and every patient regarding the health-care system and the society in general. Why has the diagnosis of depression increased over the past two decades? Are treatments offered to patients by their primary care physicians and psychiatrists justified and evidence based? Why do patients use nutritional and herbal supplements and are attracted to other complementary therapies? How do pharmaceutical companies exploit the health-care system and influence physicians to prescribe not the most effective but most expensive medicines? What is St. John's wort, and who has been using this unassuming weed for health benefits? The effectiveness of antidepressant drugs, both typical and newer drug classes, like SSRIs and SNRIs, and their adverse effects have been presented. The author has made head-to-head comparisons of scientific studies of St. John's wort with SSRIs, such as Prozac, Paxil, and Zoloft, for their effectiveness, adverse effects, and potentials for drug interactions in cogent and easily understood manner. The author leaves the reader with a take-home message as he concludes this book.

New Look to Phytomedicine: Advancements in Herbal Products as Novel Drug Leads is a compilation of in-depth information on the phytopharmaceuticals used in modern medicine for the cure and management of difficult-to-treat and challenging diseases. Readers will find cutting-edge knowledge on the use of plant products with scientific validation, along with updates on advanced herbal medicine in pharmacokinetics and drug delivery. This authoritative book is a comprehensive collection of research based, scientific validations of bioactivities of plant products, such as anti-infective, anti-diabetic, anti-cancer, immune-modulatory and metabolic disorders presented by experts from across the globe. Step-by-step information is presented on chemistry, bioactivity and the functional aspects of biologically active compounds. In addition, the pharmacognosy of plant products with mechanistic descriptions of their actions, including pathogenicity is updated with information on the use of nanotechnology and molecular tools in relation to herbal drug research.